Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L, Sofen H, Pink AE, Esfandiari E, Arai T, Yang Y, Shi R, Barragan C, Kricorian G, Schwartz-Sagi L, Bissonnette R

Open source

DOI: 10.1016/s0140-6736(25)01865-3
Published: 2026 Jan 3
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-01865-3,
  title = {Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.},
  author = {Guttman-Yassky E and Kabashima K and Worm M and Luna PC and Hong HC and Chovatiya R and Bernstein JA and Kern JS and Ehst BD and Magnolo N and Herranz-Pinto P and Stein Gold L and Sofen H and Pink AE and Esfandiari E and Arai T and Yang Y and Shi R and Barragan C and Kricorian G and Schwartz-Sagi L and Bissonnette R},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(25)01865-3},
  url = {https://doi.org/10.1016/s0140-6736(25)01865-3}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
AU  - Guttman-Yassky E
AU  - Kabashima K
AU  - Worm M
AU  - Luna PC
AU  - Hong HC
AU  - Chovatiya R
AU  - Bernstein JA
AU  - Kern JS
AU  - Ehst BD
AU  - Magnolo N
AU  - Herranz-Pinto P
AU  - Stein Gold L
AU  - Sofen H
AU  - Pink AE
AU  - Esfandiari E
AU  - Arai T
AU  - Yang Y
AU  - Shi R
AU  - Barragan C
AU  - Kricorian G
AU  - Schwartz-Sagi L
AU  - Bissonnette R
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(25)01865-3
UR  - https://doi.org/10.1016/s0140-6736(25)01865-3
ER  -

APA

E, G., K, K., M, W., PC, L., HC, H., R, C., JA, B., JS, K., BD, E., N, M., P, H., L, S. G., H, S., AE, P., E, E., T, A., Y, Y., R, S., C, B., G, K., L, S., & R, B. (2026). Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(25)01865-3

Source records

pubmed · retrieved 2026-09-26T06:28:42.971Z